{
    "medicine_id": "d08dc896898eeb66b5b10fea89aef37654676868",
    "platform_id": "DB09144",
    "metadata": {
        "name": "Vistogard 951 mg 1g Granule",
        "composition": "951 mg 1g Uridine triacetate",
        "clinical_particulars": {
            "therapeutic_indications": "Marketed as the product Xuriden FDA uridine triacetate is indicated for the treatment of hereditary orotic aciduria Marketed as the product Vistogard FDA uridine triacetate is indicated for the emergency treatment of adult and pediatric patients in the following situations following a fluorouracil or capecitabine overdose regardless of the presence of symptoms or who exhibit early onset severe or life threatening toxicity affecting the cardiac or central nervous system and or early onset unusually severe adverse reactions e g gastrointestinal toxicity and or neutropenia within 96 hours following the end of fluorouracil or capecitabine administration",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}